An experimental vaccine strategy has, for the first time, reliably generated broadly neutralizing antibodies (bnAbs) against HIV in every subject tested.
A collaborative study published in Nature on April 29, 2026, has demonstrated a breakthrough in HIV research. Scientists from Karolinska Institutet, The Scripps Research Institute, and Emory University successfully induced broadly neutralizing antibodies in all six vaccinated rhesus macaques.
Key Findings
- The vaccine strategy induced antibodies capable of neutralizing multiple genetically distinct HIV strains in all six vaccinated rhesus macaques.
- The antibodies targeted the apex of the HIV envelope spike protein, a conserved region of the virus.
- The neutralization activity achieved was classified as tier-2 cross-neutralization, a benchmark in the field.
- The antibodies were confirmed by electron microscopy to bind to the spike apex similarly to bnAbs isolated from some humans living with HIV.
This marks the first time a vaccination strategy has reliably produced broadly cross-neutralizing antibodies against HIV in every subject tested in a study setting.
Methodology
The vaccine design involved a multi-step process. Researchers first screened a library of stabilized HIV spike proteins to identify those capable of activating rare precursor immune cells necessary for producing apex-targeting bnAbs. Selected proteins were then attached to liposomes (nanoparticles) to present multiple copies of the virus's surface protein to the immune system simultaneously.
Macaques were administered a prime vaccination with one spike protein, followed by booster doses containing spike proteins that were gradually altered across different HIV strains. The objective was to train the immune system to recognize and respond to features shared across diverse HIV variants.
Results
All vaccinated animals developed antibodies that bound to the virus's apex and neutralized a range of HIV strains not included in the vaccine. The antibodies were classified as achieving tier-2 cross-neutralization.
Limitations and Next Steps
The experimental vaccine is not yet ready for human trials. Manufacturing clinical-grade nanoparticles is technically demanding and costly. The research team is exploring alternative delivery methods, including mRNA-based approaches. Discussions are ongoing regarding potential clinical studies.
Publication Details
The study, titled "Vaccine generates broadly cross-neutralizing antibodies to the HIV Env apex," was published in Nature with the DOI: 10.1038/s41586-026-10429-3. Funding was provided by the US National Institutes of Health. The researchers declared no conflicts of interest.